DelveInsight’s “Basal Cell Neoplasms Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Basal Cell Neoplasms pipeline landscape. It covers the Basal Cell Neoplasms Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Basal Cell Neoplasms Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/basal-cell-neoplasms-pipeline-insight
Key Takeaways from the Basal Cell Neoplasms Pipeline Report
- On January 26, 2026- Highlight Therapeutics initiated a phase 2b clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma.
- DelveInsight’s Basal Cell Neoplasms Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Basal Cell Neoplasms treatment.
- The leading Basal Cell Neoplasms Companies such as Sol-Gel Technologies, AiViva BioPharma Inc., Feldan Therapeutics, Incyte Corporation, Verrica Pharmaceuticals Inc., Senhwa Biosciences, Turn Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Sol-Gel Technologies, Palvella Therapeutics/TransDerm and others.
- Promising Basal Cell Neoplasms Therapies such as Remetinostat, Pembrolizumab, Vismodegib, AIV001, Nivolumab, STP705, BO-112, SP-002, ERIVEDGE, Ipilimumab, Relatlimab, ASN-002, Sinecatechins 10% and others.
Want to know which companies are leading innovation in Basal Cell Neoplasms? @ Basal Cell Neoplasms Clinical Trials Assessment
The Basal Cell Neoplasms Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Basal Cell Neoplasms Pipeline Report also highlights the unmet needs with respect to the Basal Cell Neoplasms.
Basal Cell Neoplasms Overview
Basal cell neoplasms, commonly referred to as basal cell carcinomas (BCCs), are the most common form of skin cancer. These tumors arise from the basal cells, which are located in the lowest layer of the epidermis. While BCCs are typically slow-growing and rarely metastasize, they can be locally invasive and cause significant damage to surrounding tissues if not treated. BCCs are most frequently found in sun-exposed areas of the skin, such as the face, neck, and hands, and their incidence increases with age and cumulative sun exposure.
Basal Cell Neoplasms Emerging Drugs Profile
- Patidegib: Sol-Gel Technologies
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib, the active substance in SGT-610, is designed to block the SMO signal, thus, allowing cells to function normally and reducing the production of new tumors. Currently, the drug is in the Phase III stage of its development for the treatment of Basal Cell Carcinoma.
- AIV001: AiViva BioPharma, Inc.
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. In nonclinical in vivo studies, AIV001 demonstrated reduced dermal neovascularization and fibroplasia in wound healing models and long residence time in the skin with a single treatment. AiViva has completed a Phase I/IIa clinical trial of AIV001 for the incisional scarring and wound healing and has completed a clinical trial for nonmelanoma skin cancer.
If you’re tracking ongoing Basal Cell Neoplasms Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Basal Cell Neoplasms Treatment Drugs
The Basal Cell Neoplasms Pipeline report provides insights into:-
- The report provides detailed insights about companies that are developing therapies for the treatment of Basal Cell Neoplasms with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Basal Cell Neoplasms Treatment.
- Basal Cell Neoplasms Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Basal Cell Neoplasms Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Basal Cell Neoplasms market.
Basal Cell Neoplasms Companies
Sol-Gel Technologies, AiViva BioPharma Inc., Feldan Therapeutics, Incyte Corporation, Verrica Pharmaceuticals Inc., Senhwa Biosciences, Turn Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Sol-Gel Technologies, Palvella Therapeutics/TransDerm and others.
Basal Cell Neoplasms Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Basal Cell Neoplasms Products have been categorized under various Molecule types such as,
- Monoclonal antibody
- Small molecule
- Peptide
From emerging drug candidates to competitive intelligence, the Basal Cell Neoplasms Pipeline Report covers it all – check it out now @ Basal Cell Neoplasms Market Drivers and Barriers, and Future Perspectives
Scope of the Basal Cell Neoplasms Pipeline Report
- Coverage- Global
- Basal Cell Neoplasms Companies- Sol-Gel Technologies, AiViva BioPharma Inc., Feldan Therapeutics, Incyte Corporation, Verrica Pharmaceuticals Inc., Senhwa Biosciences, Turn Therapeutics, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Sol-Gel Technologies, Palvella Therapeutics/TransDerm and others.
- Promising Basal Cell Neoplasms Therapies- Remetinostat, Pembrolizumab, Vismodegib, AIV001, Nivolumab, STP705, BO-112, SP-002, ERIVEDGE, Ipilimumab, Relatlimab, ASN-002, Sinecatechins 10% and others.
- Basal Cell Neoplasms Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Basal Cell Neoplasms Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover what’s next for the Basal Cell Neoplasms Treatment landscape in this detailed analysis @ Basal Cell Neoplasms Emerging Drugs and Major Players
Table of Contents
- Introduction
- Executive Summary
- Basal Cell Neoplasms: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Basal Cell Neoplasms– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Patidegib: Sol-Gel Technologies
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I/II)
- AIV001: AiViva BioPharma, Inc.
- Preclinical and Discovery Stage Products
- Inactive Products
- Basal Cell Neoplasms Key Companies
- Basal Cell Neoplasms Key Products
- Basal Cell Neoplasms- Unmet Needs
- Basal Cell Neoplasms- Market Drivers and Barriers
- Basal Cell Neoplasms- Future Perspectives and Conclusion
- Basal Cell Neoplasms Analyst Views
- Basal Cell Neoplasms Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
